Back to Search
Start Over
Towards a cancer mission in Horizon Europe: recommendations
- Source :
- Molecular Oncology, Vol 14, Iss 8, Pp 1589-1615 (2020), Molecular Oncology, Scientia
- Publication Year :
- 2020
-
Abstract
- A comprehensive cancer approach covering the entire research–care–prevention continuum can achieve a 10‐year cancer‐specific survival for 75% of patients diagnosed in EU member states with well‐developed health care by 2030. To ensure access to a critical mass of patient biological and technological resources, infrastructures for translational research, clinical and prevention trials, and outcomes research are needed. Here, we provide recommendations for achieving key targets and prioritize research areas.<br />A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research–care–prevention continuum has the potential to achieve in 2030 a 10‐year cancer‐specific survival for 75% of patients diagnosed in European Union (EU) member states with a well‐developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high‐quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science‐driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC‐like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long‐term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans‐border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence‐based advice.
- Subjects :
- 0301 basic medicine
Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]
Cancer Research
Process management
Palliative care
Biomedical
Translational Research, Biomedical
0302 clinical medicine
Cancer Survivors
cancer mission
cancer research/care/prevention continuum
comprehensive cancer centres
European healthcare systems
patient empowerment
science policy
Clinical Trials as Topic
Europe
Humans
Neoplasms
Organizational Innovation
Palliative Care
Patient Participation
Specialization
media_common
General Medicine
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Medicina - Investigació
Oncology
Natural Science Disciplines::Science::Research::Biomedical Research::Translational Medical Research [DISCIPLINES AND OCCUPATIONS]
030220 oncology & carcinogenesis
Molecular Medicine
Càncer - Prevenció
disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica::investigación médica traslacional [DISCIPLINAS Y OCUPACIONES]
Science policy
medicine.medical_specialty
Translational research
Harmonization
lcsh:RC254-282
neoplasias [ENFERMEDADES]
Critical mass (sociodynamics)
Other subheadings::Other subheadings::/prevention & control [Other subheadings]
03 medical and health sciences
Translational Research
Genetics
medicine
media_common.cataloged_instance
European union
Neoplasms [DISEASES]
030104 developmental biology
Policy Article
Portfolio
Business
Outcomes research
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Molecular Oncology, Vol 14, Iss 8, Pp 1589-1615 (2020), Molecular Oncology, Scientia
- Accession number :
- edsair.doi.dedup.....da36c5f61c979213e70bcb1ed8a224c5